Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate

05.04.24 11:33 Uhr

Werte in diesem Artikel

121,00 EUR 0,00 EUR 0,00%

167,60 EUR -2,25 EUR -1,32%




1.615,0 PKT 1,5 PKT 0,09%

18.693,4 PKT 2,1 PKT 0,01%

7.195,0 PKT -0,7 PKT -0,01%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

189,8 PKT 0,7 PKT 0,38%

39.069,6 PKT 4,3 PKT 0,01%

521,8 PKT -0,2 PKT -0,04%

9.961,4 PKT 0,9 PKT 0,01%

18.700,0 PKT 115,0 PKT 0,62%

18.679,1 PKT 65,3 PKT 0,35%

15.248,7 PKT -196,7 PKT -1,27%

7.362,9 PKT 0,2 PKT 0,00%

16.939,8 PKT 9,0 PKT 0,05%

2.533,1 PKT 17,9 PKT 0,71%

5.304,7 PKT 36,9 PKT 0,70%

18.701,0 PKT 107,4 PKT 0,58%

Merck MRK has initiated phase III study on its oral KRAS G12C inhibitor candidate, MK-1084, for first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC).The study will evaluate MK-1084 in combination with Merck’s blockbuster PD-L1 inhibitor Keytruda in patients with metastatic NSCLC whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%). In some early studies, MK-1084, in combination with Keytruda, has demonstrated some promising anti-tumor activity, The study will enroll approximately 600 patients globally. The primary endpoints of the study are progression-free survival and overall survival while some key secondary endpoints are objective response rate and duration of response.MK-1084 is currently being evaluated in a phase I study as a monotherapy as well as in combination with other therapies for KRAS G12C mutant advanced solid tumors.Merck’s stock has risen 13.6% in the past year compared with an increase of 3.7% for the industry. Image Source: Zacks Investment Research Tumors characterized by KRAS mutations are commonly associated with poor prognosis and resistance to therapy. KRAS is a well-validated oncology target. KRAS G12C is the most common KRAS mutation in NSCLC. KRAS inhibitors are developed to inhibit KRAS mutations and can address an area of significant unmet medical need for the treatment of cancer.Some FDA-approved KRAS drugs are Bristol-Myers’ BMY Krazati and Amgen’s AMGN Lumakras for KRASG12C-mutated locally advanced or metastatic NSCLC. Krazati was added to Bristol-Myers’ portfolio with the acquisition of Mirati Therapeutics earlier this year.Amgen’s Lumakras is also being investigated in previously treated KRAS G12C-mutated colorectal cancer as monotherapy and in combination with other therapies. Lumakras is in phase I and phase II development for earlier lines of NSCLC as monotherapy and in combination with other therapies.Bristol-Myers’ Krazati is further being evaluated in multiple label expansion studies, both as monotherapy and in combination with other drugs, across multiple cancer indications.Jazz Pharmaceuticals JAZZ entered into a definitive agreement with U.K.-based biotech Redx Pharma in February 2024 to acquire global rights to the latter’s preclinical KRAS inhibitor program. Jazz and Redx will jointly advance the investigational new drug (IND)-enabling activities for the candidates under this collaboration. However, Jazz will be solely responsible for all clinical development, regulatory and commercialization activities for these candidates.Merck has a Zacks Rank #3 (Hold) currently. You can see the complete list of today’s Zacks #1 Rank stocks here.Merck & Co., Inc. Price and Consensus Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. QuoteTop 5 ChatGPT Stocks RevealedZacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”Download Free ChatGPT Stock Report Right Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis ReportTo read this article on click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Kras d.d.

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Kras d.d.


Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
05.08.2022Merck HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"